Universal reference book for medicines
Product name: TAZOZIN (TAZOCIN)

Active substance: piperacillin, tazobactam

Type: Antibiotic of a broad-spectrum penicillin group with a beta-lactamase inhibitor

Manufacturer: WYETH WHITEHALL EXPORT (Austria) manufactured by WYETH LEDERLE (Italy)
Composition, form of production and packaging
Lyophilizate for the preparation of a solution for intravenous administration
in the form of powder or porous mass from almost white to white.

1 f.

piperacillin sodium 2.0849 g,

which corresponds to the content of piperacillin monohydrate 2 g

tazobactam sodium 268.3 mg,

which corresponds to the content of tazobactam 250 mg

[PRING] sodium citrate dihydrate, disodium edetate dihydrate.

Vials of colorless glass with a capacity of 30 ml (12) - packs of cardboard.

Lyophilizate for the preparation of a solution for intravenous administration in the form of powder or porous mass from almost white to white.

1 f.

piperacillin sodium 4.1699 g,

which corresponds to the content of piperacillin monohydrate 4 g

tazobactam sodium 536.6 mg,

which corresponds to the content of tazobactam 500 mg

[PRING] sodium citrate dihydrate, disodium edetate dihydrate.

Bottles of colorless glass with a capacity of 70 ml (12) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

The product description was approved by the manufacturer for the 2009 print edition.

PHARMACHOLOGIC EFFECT

Piperacillin monohydrate (piperacillin) is a semi-synthetic bactericidal broad-spectrum antibiotic that is active against many gram-positive and gram-negative aerobic and anaerobic bacteria.

Piperacillin inhibits the synthesis of the membrane of the cell wall of the microorganism.
Tazobactam is a sulfonic derivative of triazolmethylpenicillic acid, a potent inhibitor of many? -lactamases (including plasmid and chromosomal beta-lactamases), which often cause resistance to penicillins and cephalosporins, including. third generation cephalosporins. The presence of tazobactam in the combined Tazocin preparation increases antimicrobial activity and expands the spectrum of piperacillin action by including many β-lactamase-producing bacteria that are usually resistant to piperacillin and other beta-lactam antibiotics. Thus, Tazocin combines the properties of a broad-spectrum antibiotic and an α-lactamase inhibitor.
Tazocin is active against gram-negative bacteria: producing and non-producing β-lactamase strains, Escherichia coli, Citrobacter spp.
(including Citrobacter freundii, Citrobacter diversus), Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae), Enterobacter spp. (including Enterobacter cloacae, Enterobacter aerogenes), Proteus vulgaris, Proteus mirabilis, Providencia rettgery, Providencia stuartii, Plesiomonas shigelloides, Morganella morganii, Serratia spp. (including Serratia marcescens, Serratia liquifaciens), Salmonella spp., Shigella spp., Pseudomonas aeruginosa and other Pseudomonas spp. (including Pseudomonas cepacia, Pseudomonas fluorescens), Xanthamonas maltophilia, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella spp. (including Branhamella catarrhalis), Acinetobacter spp., Haemophilus influenzae, Haemophilus parainfluenzae, Pasteurella multocida, Yersinia spp., Campylobacter spp., Gardnerella vaginalis.
In vitro, the synergistic activity of the combination piperacillin / tazobactam and aminoglycosides with multidrug-resistant Pseudomonas aeruginosa was noted.

Tazocin is active against Gram-positive bacteria: producing and non-producing β-lactamase strains of Streptococcus spp.
(including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus bovis, Streptococcus agalactiae, Sfreptococcus viridance of group C, group G), Enterococcus spp. (Enterococcus faecalis, Enterococcus faechtm), Staphylococcus aureus (methicillin-sensitive), Staphylococcus saprophytics, Staphylococcus epidermidis (coagulase-negative), Corynebacteria spp., Listeria monocytogenes, Nocardia spp.
Tazocin is active against anaerobic bacteria: producing and non-producing β-lactamase, such as Bacteroides spp.
(Bacteroides bivius, Bacteroides disiens, Bacteroides capillosus, Bacteroides melaninogenicus, Bacteroides oralis, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides asaccharolyticus), Peptosfreptococcus spp., Fusobacterium spp., Eubacterium spp., Clostridium spp. (including Clostridium difficile, Clostridium parfringens), Veilonella spp. and Actynomyces spp.
The following are the minimum inhibitory concentrations (MIC)

Sensitive moderately sensitive resistant

Enterobacteriaceae <16 mg / l 32-64 mg / l> 128 mg / l

Pseudomonas spp.
<64 mg / l -> 128 mg / l
Staphylococcus spp.
<8 mg / l -> 16 mg / l
* Streptococcus spp.
<1 mg / l -> 2 mg / l
Anaerobes <32 mg / L 64 mg / l> 128 mg / l

* The prevalence of acquired resistance may vary in different geographic areas and time periods for individual species.

PHARMACOKINETICS

Distribution

The mean concentrations of piperacillin and tazobactam in plasma in equilibrium are presented in Tables 1-2.
C max piperacillin and tazobactam in plasma are reached immediately after completion of IV administration. The concentration of piperacillin administered in combination with tazobactam is similar to that of administering piperacillin in an equivalent dose as monotherapy.
Table 1. Levels of equilibrium plasma concentrations in adults after 5-minute IV injection of piperacillin / tazobactam.

Levels of tazobactam concentration in plasma (μg / ml)

The dose of piperacillin / tazobactam 5 ** min 30 min 1 h 2 h 3 h 4 h

2 g / 250 mg 237 76 38 13 6 3

4 g / 500 mg 364 165 92 37 16 7

Levels of tazobactam concentration in plasma (μg / ml)

The dose of piperacillin / tazobactam 5 ** min 30 min 1 h 2 h 3 h 4 h

2 g / 250 mg 23.4 8.0 4.5 1.7 0.9 0.7

4 g / 500 mg 34.3 17.9 10.8 4.8 2.0 0.9

** End of the 5-minute introduction

Table 2. Levels of equilibrium plasma concentrations in adults after a 30-minute IV injection of piperacillin / tazobactam

Levels of plasma piperazillin concentration (μg / ml)

The dose of piperacillin / tazobactam 30 ** min 1 h 1.5 h 2 h 3 h 4 h

2 g / 250 mg 134 57 29 17 5 2

4 g / 500 mg 298 141 87 47 16 7

Levels of tazobactam concentration in plasma (μg / ml)

The dose of piperacillin / tazobactam 30 ** min 1 h 1.5 h 2 h 3 h 4 h

2 g / 250 mg 14.8 7.2 4.2 2.6 1.1 0.7

4 g / 500 mg 33.8 17.3 11.7 6.8 2.8 1.3

** End of the 30-minute introduction

With an increase in the dose of the combination piperacillin 2 g / tazobactam 250 g to 4 g / 500 mg, respectively, a disproportionate increase in the levels (approximately 28%) of the concentration of piperacillin and tazobactam is observed.

The binding with proteins of both piperacillin and tazobactam is approximately 30%, while the presence of tazobactam does not affect the binding of piperacillin, and the presence of piperacillin on the binding of tazobactam.

Piperacillin / tazobactam is widely distributed in tissues and body fluids, incl.
in the intestinal mucosa, mucous membrane of the gallbladder, lungs, bile, female reproductive system (uterus, ovaries and fallopian tubes) and bones. The average concentrations in tissues are from 50 to 100% of the concentration in the plasma.
Data on penetration through the BBB is not available.

Biotransformation

As a result of metabolism, piperacillin is converted into a low-activity desethyl derivative;
tazobactam - in the inactive metabolite.
Excretion

Piperacillin and tazobactam are excreted by the kidneys through glomerular filtration and tubular secretion.
Piperacillin is rapidly excreted unchanged, 68% of the dose is detected in the urine. Tazobactam and its metabolites are rapidly excreted by renal excretion, 80% of the dose taken is unchanged, and the remaining amount is in the form of metabolites. Piperacillin, tazobactam and desethylpiperacillin are also excreted with bile.
After the administration of single and repeated doses of Tazocin to a healthy subject, T 1/2 piperacillin and tazobactam from the plasma ranged from 0.7 to 1.2 hours and did not depend on the dose of the drug or the duration of the infusion.
With a decrease in the creatinine clearance of T 1/2, piperacillin and tazobactam are lengthened.
Pharmacokinetics in special clinical cases

As the creatinine clearance of T 1/2 decreases, piperacillin and tazobactam increase.
With a decrease in creatinine clearance below 20 ml / min, T 1/2 piperacillin and tazobactam, respectively, increase 2 and 4 times, compared with those in patients with normal renal function.
During hemodialysis, 30 to 50% of piperacillin and 5% of the dose of tazobactam in the form of a metabolite are excreted.
When peritoneal dialysis is performed, respectively, about 6 and 21% of piperacillin and tazobactam, with 18% of tazobactam derived in the form of its metabolite.
Although in patients with impaired liver function, T 1/2 of piperazillin and tazobactam are increased, no dose adjustment is required.

INDICATIONS

Tazocine is used to treat systemic and / or local bacterial infections caused by microorganisms sensitive to piperacillin / tazobactam.

Adults and children over 12 years of age

- Lower respiratory tract infection;

- urinary tract infections (complicated and uncomplicated);

- intra-abdominal infections;

- skin and soft tissue infections;

- septicemia;

- gynecological infections (including endometritis and adnexitis in the postpartum period);

- bacterial infections in patients with neutropenia (in combination with aminoglycosides);

- infections of bones and joints;

- Mixed infections (caused by Gram-positive / Gram-negative aerobic and anaerobic microorganisms).

Children from 2 to 12 years old

- intra-abdominal infections;

- infections against neutropenia (in combination with aminoglycosides).

DOSING MODE

Tazocin is administered iv in slowly struino for at least 3-5 minutes or drip for 20-30 minutes.

Doses of the drug and the duration of treatment are determined by the severity of the infectious process and the dynamics of clinical and bacteriological indicators.

Adults and children over 12 years with normal renal function

The recommended daily dose is 12 g piperacillin / 1.5 g tazobactam, which is divided for several injections every 6-8 hours.

The total daily dose depends on the severity and localization of the infection.
The daily dose can reach 18 g of piperacillin / 2.25 g of tazobactam, which is divided for several administrations.
Children from 2 to 12 years old

For neutropenia in patients with normal kidney function and body weight less than 50 kg, the dose of Tazocin is 90 mg (80 mg piperacillin / 10 mg tazobactam) per kg body weight, which is administered every 6 hours in combination with the appropriate dose of aminoglycoside.

In children with a body weight of more than 50 kg, the dose corresponds to an adult, and is administered in combination with aminoglycosides.

With intra-abdominal infection in children with a body weight of up to 40 kg and normal kidney function, the recommended dose is 100 mg of piperacillin / 12.5 mg of tazobactam per kg of body weight every 8 hours.

Children with a body weight of more than 40 kg and normal kidney function are given the same dose as adults.

Treatment should be conducted for at least 5 days and not more than 14 days, given that the administration of the drug is continued for at least 48 hours after the disappearance of clinical signs of infection.

Impaired renal function

Patients with renal insufficiency or a patient on hemodialysis , dose and frequency of administration should be adjusted to the degree of impaired renal function.

Recommended doses of the drug for adults and children (body weight> 50 kg) with renal failure

Creatinine clearance (mL / min.) Recommended doses of piperacillin / tazobactam

> 40 No dose adjustments required

20-40 12 g / 1.5 g / day 4 g / 500 mg every 8 h

<20 8 g / 1 g / day 4 g / 500 mg every 12 h

For patients on hemodialysis , the maximum daily dose is 8 g / 1 g of piperacillin / tazobactam.
In addition, since 30-50% piperacillin is withdrawn from the hemodialysis within 4 hours, one additional dose of 2 g / 250 mg piperacillin / tazobactam should be given after each dialysis session.
Children 2-12 years old with renal insufficiency

The pharmacokinetics of piperacillin / tazobactam in children with renal insufficiency have not been studied.
Data on the doses of the drug with a combination of renal failure and neutropenia are absent. For children 2-12 years of age with renal insufficiency, it is recommended to adjust the dose of Tazocin as follows:
Recommended doses of the drug for children (body weight <50 kg) with renal failure

Such a change in dose is only indicative.
Each patient should be closely monitored for the timely detection of signs of an overdose. It is necessary to adjust the dose of the drug and the interval between its administration accordingly.
Clearance of creatinine Recommended doses of piperacillin / tazobactam

> 50 ml / min 112.5 mg / kg (100 mg piperacillin / 12.5 mg tazobactam) every 8 hours

<50 ml / min 78.75 mg / kg (70 mg piperacillin / 8.75 mg tazobactam) every 8 hours

There is no need for dose adjustments for liver function disorders .

In elderly patients, dose adjustment is necessary only if there is a violation of kidney function.

Recommendations for the preparation of solution

Tazocine is used only for IV administration!
The preparation is dissolved in one of the following solvents in accordance with the indicated volumes. The vial is rotated in a circular motion until the content is completely dissolved (with constant rotation, usually for 5-10 min). The prepared solution is a colorless or pale yellow liquid.
Dosage / vial (piperacillin / tazobactam) Required volume of solvent

2 g + 250 mg of 10 ml

4 g + 500 mg 20 ml

Solvents compatible with Tazotine: 0.9% sodium chloride solution, sterile water for injection, 5% dextrose solution, Ringer's lactate solution.

Then the prepared solution can be diluted to the required volume (for example, from 50 ml to 150 ml) by one of the following compatible solvents: 0.9% sodium chloride solution, sterile water for injection (maximum recommended volume is 50 ml), 5% dextrose solution, Ringer's lactate solution.
The prepared solution should be used within 24 hours after preparation when stored at a temperature of no higher than 25 ° C or for 48 hours when stored at a temperature of 2 ° to 8 ° C.
SIDE EFFECT

The following side effects were classified as follows: very often (? 10%), often (? 1%, but <10%), infrequently (? 0.1%, but <1%), rarely (± 0.01%, but <0.1% ), very rarely (<0.01%), including isolated cases.

Superinfections: infrequently - fungal superinfections.

From the hemopoietic system: infrequently - leukopenia, neutropenia, thrombocytopenia;
rarely anemia, bleeding (including purpura, epistaxis, increased bleeding time), eosinophilia, hemolytic anemia; very rarely - agranulocytosis, positive direct Coombs test, pancytopenia, increased partial thromboplastin time, increased prothrombin time, thrombocytosis.
Allergic reactions: rarely anaphylactic / anaphylactoid reaction (including anaphylactic shock).

From the side of metabolism: very rarely - hypoalbuminemia, hypoglycemia, hypoproteinemia, hypokalemia.

From the side of the central nervous system: infrequently - headache, insomnia;
rarely convulsions.
From the cardiovascular system: infrequently - hypotension, phlebitis, thrombophlebitis;
rarely - flushes of blood to the skin of the face.
On the part of the digestive system: often - diarrhea, nausea, vomiting;
infrequent - constipation, dyspepsia, jaundice, stomatitis, increased activity of hepatic transaminases (ALT, ACT); rarely - abdominal pain, pseudomembranous colitis, hyperbilirubinemia, increased activity of alkaline phosphatase, increased activity of GGT, hepatitis.
Dermatological reactions: often - a rash;
infrequently - itching, hives; rarely - bullous dermatitis, erythema multiforme; very rarely - Stevens-Johnson syndrome, toxic epidermal necrolysis.
From the musculoskeletal system: rarely - arthralgia.

From the side of the urinary system: infrequently - increasing the concentration of creatinine in the blood serum;
rarely - Interstitial nephritis, kidney failure; very rarely - an increase in the concentration of urea in the blood serum.
Other: infrequent - fever, local reactions (redness, condensation at the injection site).

CONTRAINDICATIONS

- Children under 2 years;

- Hypersensitivity to beta-lactam drugs (including penicillins, cephalosporins), other components of the drug or to inhibitors of α-lactamases.

With caution

Severe bleeding (including history), cystic fibrosis (increased risk of hyperthermia and skin rash), pseudomembranous enterocolitis, childhood, pregnancy, lactation, renal failure (creatinine clearance below 20 ml / min), patients on hemodialysis, co-administration of high doses of anticoagulants, hypokalemia.

PREGNANCY AND LACTATION

There is insufficient data on the use of a combination of piperacillin / tazobactam or both drugs separately in pregnant women.
Piperacillin and tazobactam penetrate the placental barrier. Pregnant women drug can be prescribed only in those cases when the expected benefit for the mother exceeds the possible risk to the fetus.
Piperacillin in low concentrations is secreted with breast milk;
the isolation of tazobactam in milk has not been studied. The drug can be prescribed to women who breastfeed only if the expected benefit to the mother exceeds the possible risk for the breastfed baby, or breastfeeding should be stopped at the time of treatment.
APPLICATION FOR FUNCTIONS OF THE LIVER

Patients with renal insufficiency or a patient on hemodialysis , dose and frequency of administration should be adjusted to the degree of impaired renal function.

Recommended doses of the drug for adults and children (body weight> 50 kg) with renal failure

Creatinine clearance (mL / min.) Recommended doses of piperacillin / tazobactam

> 40 No dose adjustments required

20-40 12 g / 1.5 g / day 4 g / 500 mg every 8 h

<20 8 g / 1 g / day 4 g / 500 mg every 12 h

For patients on hemodialysis , the maximum daily dose is 8 g / 1 g of piperacillin / tazobactam.
In addition, since 30-50% piperacillin is withdrawn from the hemodialysis within 4 hours, one additional dose of 2 g / 250 mg piperacillin / tazobactam should be given after each dialysis session.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

There is no need for dose adjustments for liver function disorders .

APPLICATION FOR CHILDREN

Children from 2 to 12 years old

When neutropenia in patients children with normal renal function and weighing less than 50 kg dose tazocin 90 mg (80 mg of piperacillin / tazobactam 10 mg) per kg body weight, which is administered every six hours in combination with an appropriate dose of aminoglycoside.
In children weighing more than 50 kg dose corresponds to an adult, and it is administered in combination with aminoglycosides.
When intra-abdominal infections in children weighing up to 40 kg and normal renal function, the recommended dose is 100 mg of piperacillin / 12.5 mg of tazobactam per kg of body weight every 8 hours.
For children weighing more than 40 kg and normal renal function is assigned the same dose as adults.
Treatment should be for at least 5 days and not more than 14 days, taking into account the fact that the administration is continued for at least 48 hours after the disappearance of clinical signs of infection.
Renal dysfunction
patients with kidney failure or patients on hemodialysis , dose and frequency of administration should be adjusted according to the degree of renal impairment.
Recommended doses for children and adults (body weight> 50 kg) in renal failure
Creatinine clearance (ml / min). Recommended doses of piperacillin / tazobactam
> 40 dose adjustment is required
20-40 12 g / 1.5 g / day to 4 g / 500 mg every 8 hr
<20 8 g / 1 g / day to 4 g / 500 mg every 12 hours
forpatients undergoing hemodialysis , the maximum daily dose is 8 g / 1 g of piperacillin / tazobactam. Furthermore, since during hemodialysis for 4 hours 30-50% of piperacillin is output, should be administered one additional dose of 2 g / 250 mg of piperacillin / tazobactam after each dialysis session.
Children 2-12 years of age with renal insufficiency
The pharmacokinetics of piperacillin / tazobactam in children with renal impairment has not been studied. Data on doses of the drug at a combination of renal insufficiency and neutropenia no. For children 2-12 years of age with renal insufficiency, it is recommended to adjust the dose tazocin follows:
Recommended doses for children (body weight <50 kg) in patients with renal insufficiency
Such a change in dose is only indicative. Each patient should be closely monitored for early signs of overdose. It is necessary to appropriately adjust the dose and the interval between its introduction.
Creatinine clearance Recommended doses of piperacillin / tazobactam
> 50 ml / min 112.5 mg / kg (100 mg of piperacillin / tazobactam 12.5 mg) every 8 hours
<50 ml / min 78.75 mg / kg (70 mg tazobactam piperacillin /8.75 mg) every 8 hours
No experience of use in children below 2 years of age.
APPLICATION IN ELDERLY PATIENTS

In elderly patients a dose adjustment is necessary only in the presence of renal impairment.
SPECIAL INSTRUCTIONS

Before treatment tazocin should interrogate patient detail to identify potential hypersensitivity reactions in history, including associated with penicillins or cephalosporins. Severe allergic reactions are more likely to develop in patients with increased sensitivity to multiple allergens. These reactions require discontinuation of the drug and the appointment of epinephrine (adrenaline) and conduct other emergency measures.
Antibiotic associated pseudomembranous colitis may appear severe, prolonged diarrhea, life threatening. Pseudomembranous colitis may develop in the period of antibiotic therapy and after its completion. In such cases, stop administering tazocin and prescribe appropriate therapy (e.g., vancomycin, metronidazole, p.o.). Drugs that inhibit peristalsis are contraindicated.
When treating tazocin, especially long-term, may develop leukopenia and neutropenia, therefore it is necessary to periodically monitor peripheral blood.
Patients with kidney failure or patients on hemodialysis, dose and frequency of administration should be adjusted according to the degree of renal impairment.
In some cases (most commonly in patients with renal insufficiency) is probably the appearance of increased bleeding and associated changes in laboratory parameters of blood coagulation (clotting time, platelet aggregation and prothrombin time). When the bleeding should abolish drug treatment and prescribe appropriate therapy.
It is necessary to bear in mind the possibility of the emergence of resistant organisms, which can cause superinfection, especially during long-term course of treatment tazocin.
This preparation contains 2.79 mEq. (64 mg) per gram of piperacillin sodium which can lead to an overall increase in sodium intake of patients. In patients suffering from hypokalaemia or receiving drugs that promote excretion of potassium during treatment tazocin may develop hypokalemia (you should regularly check the content of electrolytes in blood serum).
No experience of the use of children under the age of 2 years of age.
OVERDOSE

Symptoms of overdose include nausea, vomiting, diarrhea, increased neuromuscular excitability and seizures. Depending on the clinical manifestations symptomatic treatment assigned. To reduce high concentrations of piperacillin and tazobactam in the serum can be assigned to hemodialysis.
DRUG INTERACTION

Tazocin coadministration with probenecid increases T 1/2 and reduces renal clearance of both piperacillin and tazobactam, but the maximum plasma concentration of both drugs remain unchanged.
Not found pharmacokinetic interaction between tazocin and vancomycin.
Piperacillin, including and when combined with tazobactam, did not significantly affect the pharmacokinetics of tobramycin in patients with preserved renal function and patients with mild to moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam, and metabolites are also not significantly changed in the appointment of tobramycin.
Simultaneous administration of vecuronium bromide tazocin and can lead to a more prolonged neuromuscular blockade caused by the latter (a similar effect may be observed when piperacillin combined with other non-depolarizing muscle relaxants).
When concomitant administration with tazocin heparin anticoagulants or other medications that affect blood clotting system, including platelet function, you must frequently monitor the status of the blood coagulation system.
Piperacillin may delay the excretion of methotrexate (to avoid the toxic effect it is necessary to control blood serum concentration of methotrexate).
During destination tazocin possible false positive result on the sample glucose in urine using a method based on the reduction of copper ions. Therefore, it is recommended to conduct a sample based on the enzymatic oxidation of glucose.
By mixing the solutions tazocin aminoglycosides and their possible inactivation. Therefore, these drugs are recommended to be administered separately. In situations where the preferred joint appointment, solutions tazocin and aminoglycosides should be prepared separately. For administration only need to use a V-shaped catheter. If all the above conditions, tazocin be administered via V-shaped catheter with only indicated in Table aminoglycosides.
Aminoglycoside dose depends on the body weight, the nature of the infection (severe or life-threatening) and renal function (creatinine clearance).
Aminoglycoside tazocin dose tazocin, volume of solvent (ml) Aminoglycoside concentration * (mg / ml) compatible solvent
amikacin 2 g + 250 mg of 4 g + 500 mg of 5, 100, 150 1.75-7.5 0.9% sodium chloride solution or 5% dextrose solution
gentamicin 2 g + 250 mg of 4 g + 500 mg 100.150 0.7-3.32 about 0.9% sodium chloride solution
The pharmaceutical compatibility with other drugs
tazocin not be mixed in the same syringe or dropper with other drugs, in addition gentamicin, amikacin and the above solvents, since there is no information about compatibility.
In applying tazocin together with other antibiotics, drugs should be administered separately.
Given the chemical instability tazocin drug should not be used with solutions containing sodium hydrogencarbonate.
Tazocin should not be added to blood products or albumin hydrolysates.
TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

Store at a temperature not higher than 25 ° C in the reach of children.
Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!